NCT00799045View on ClinicalTrials.gov

Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

PHASE4CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

April 30, 2015

Study Completion Date

December 31, 2016

Conditions
Migraine
Interventions
DRUG

Clopidogrel

Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.

Trial Locations (1)

G1V 4G5

Hopital Laval, Québec

Sponsors
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Laval University

OTHER

NCT00799045 - Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects | Biotech Hunter | Biotech Hunter